NCT06482307View on ClinicalTrials.gov

Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 31, 2025

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
DIAGNOSTIC_TEST

[18F]-olaparib PET scan

The IMP investigated is \[18F\]Olaparib, a radiolabelled PARP inhibitor suitable for PET imaging.

Trial Locations (1)

9713 GZ

University Medical Center Groningen, Groningen

All Listed Sponsors
lead

University Medical Center Groningen

OTHER